Anti-GBP4 antibody

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary

GBP4 also known as guanylate-binding protein 4 is a member of the guanylate-binding protein family. This family is known for its role in hydrolyzing GTP to GDP and GMP an important mechanical activity that GBP4 performs. GBP4 has a mass of approximately 68 kDa. The protein is expressed in a variety of tissues but it shows higher expression in immune-related cells. It is often upregulated in response to interferon-gamma a cytokine important for immune response modulation.

Biological function summary

GBP4 plays an important role in immune response against pathogens. By disrupting microbial membranes GBP4 aids in restricting the spread of certain intracellular bacteria. It may also participate in forming a larger complex with other GBP proteins for more efficient pathogen targeting. This action is particularly significant during infections where increased GBP4 expression provides a stronger defense mechanism as part of the innate immune system.

Pathways

GBP4 integrates functionally into interferon-gamma and JAK-STAT signaling pathways. These pathways are key components of the immune response to infections and inflammation. GBP4's role in these pathways highlights its interaction with other immune proteins such as STAT1 and other guanylate-binding proteins. These interactions highlight GBP4's importance in signaling cascades that strategize cellular immune defenses.

Associated diseases and disorders

GBP4 exhibits links to conditions like autoimmune diseases and certain infections. In autoimmune pathologies dysregulation involving GBP4 may contribute to inappropriate immune activation potentially related to proteins such as interferon-gamma. Additionally in infections GBP4 plays a role in controlling bacterial infections within macrophages often in cooperation with other members of the guanylate-binding protein family. Understanding these connections provides insights into therapeutic interventions targeting immune pathways in disease management.